Connect
MJA
MJA

Pharmaceutical preparations

Complementary and alternative medicine

Making all data publicly available would be welcome

Leonie Segal, Richard H Osborne and Susan E Day

Med J Aust 2004; 181 (6): 339-340

For debate

Will the Australia–United States Free Trade Agreement undermine the Pharmaceutical Benefits Scheme?

Ken J Harvey, Thomas A Faunce, Buddhima Lokuge and Peter Drahos

Med J Aust 2004; 181 (5): 256-259

Clinical update

Major advances in bipolar disorder

Philip B Mitchell, Gin S Malhi and Jillian R Ball

Med J Aust 2004; 181 (4): 207-210 Free

Complementary and alternative medicine

The other side of the coin: safety of complementary and alternative medicine

Stephen P Myers and Phillip A Cheras

Med J Aust 2004; 181 (4): 222-225 Free

Letters

Drugs, sport and the Olympics 2000–2004

Michael C Kennedy

Med J Aust 2004; 181 (4): 227

Letter

Ciprofloxacin in the treatment of chronic suppurative otitis media

James D Kidd

Med J Aust 2004; 181 (2): 84

Complementary and alternative medicine

Good medicine and bad medicine: science to promote the convergence of “alternative” and orthodox medicine

John M Dwyer

Med J Aust 2004; 180 (12): 647-648 Free

Editorials

The beginning of the end of warfarin?

John W Eikelboom and Graeme J Hankey

Med J Aust 2004; 180 (11): 549-551

Healthcare

Impact of an electronic antibiotic advice and approval system on antibiotic prescribing in an Australian teaching hospital

M Lindsay Grayson, Sharmila Melvani, Sue W Kirsa, Stephen Cheung, M Kent Garrett, Anthony M Korman and William A Thomson

Med J Aust 2004; 180 (9): 455-458 Free

Letters

Thalidomide-induced bradycardia and its management

John Coutsouvelis and Carmela E Corallo

Med J Aust 2004; 180 (7): 366-367

Letters

Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners

Stephen J Kerr, Andrea Mant, Fiona E Horn, Kevin McGeechan and Geoffrey P Sayer

Med J Aust 2004; 180 (6): 310-312

Letters

Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners

John S Dowden

Med J Aust 2004; 180 (6): 310-312

Letters

Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners

Timothy H J Florin

Med J Aust 2004; 180 (6): 310-312

Supplement

Can we reduce disease burden from osteoarthritis?

Leonie Segal, Susan E Day, Adam B Chapman and Richard H Osborne

Med J Aust 2004; 180 (5): S11 Free

Letters

Licensing thalidomide in Australia

Colin L Crawford

Med J Aust 2004; 180 (4): 199-200

Letters

Licensing thalidomide in Australia

Martin H N Tattersall

Med J Aust 2004; 180 (4): 199-200

Letters

Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners

Mark R Nelson

Med J Aust 2004; 180 (3): 140

Letters

Effect of computerised prescribing on use of antibiotics

Ian D Coombes, Danielle A Stowasser, Charles A Mitchell and Paul Varghese

Med J Aust 2004; 180 (3): 140-141

Letters

Aspirin for cardiovascular disease prevention

Joseph Hung

Med J Aust 2004; 180 (2): 94

Editorials

Metformin and serious adverse effects

Janelle C Nisbet, Joanna M Sturtevant and Johannes B Prins

Med J Aust 2004; 180 (2): 53-54

Lessons from practice

Long-acting sulfonylureas — long-acting hypoglycaemia

Peter C Veitch and Rory J Clifton-Bligh

Med J Aust 2004; 180 (2): 84-85 Free

Letters

Aspirin for cardiovascular disease prevention

Johan H A Janssen and David Henshaw

Med J Aust 2004; 180 (2): 94

Viewpoint

The PBS community awareness campaign: how helpful is blaming patients?

Evan Doran and David A Henry

Med J Aust 2003; 179 (10): 544-545

Letters

Dosing information for paediatric patients: are they really “therapeutic orphans”?

Amanda J Caswell

Med J Aust 2003; 179 (10): 560

Editorials

Coax, COX and cola

John S Dowden

Med J Aust 2003; 179 (8): 397-398